Atogepant
Overview
Atogepant is a small molecule that acts as a calcitonin gene-related peptide (CGRP) receptor antagonist used in the prevention of migraine headaches. It is designed to provide oral preventive treatment for adult patients with episodic migraines.
API suppliers (4)
Suppliers of Atogepant evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 3 of 4 suppliers.
3 of 4 hold a GMP certificate on record in the EU or UK registers
- Macleods Pharmaceuticals Ltd.India1 active DMF GMP on record
- MSN LIFE SCIENCES PRIVATE LIMITEDIndia1 active DMF GMP on record
- Micro Labs Usa1 active DMF
- HONOUR LAB LTDIndia1 active DMF GMP on record
Patent & exclusivity (US)
Per the FDA Orange Book (3 approved US products), the latest listed US patent on Atogepant expires 27 Feb 2043 and exclusivity 28 Sept 2026. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Atogepant? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.